---
layout: default
title: Acetazolamide
parent: 僅模型預測 (L5)
nav_order: 13
evidence_level: L5
indication_count: 10
---

# Acetazolamide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ACETAZOLAMIDE: Drug Repurposing Evaluation Report

## One-Sentence Summary

Acetazolamide (DrugBank: DB00819) is a carbonic anhydrase inhibitor with known uses in glaucoma, epilepsy, and altitude sickness. However, the TxGNN model has **not yet generated any predicted new indications** for this drug, and critical data gaps remain in mechanism of action and safety information. This report serves as a **baseline data inventory** pending completion of the prediction pipeline.

---

## Quick Overview

| Item | Content |
|------|------|
| Drug Name (INN) | ACETAZOLAMIDE |
| DrugBank ID | [DB00819](https://go.drugbank.com/drugs/DB00819) |
| Original Indication | *(No approved indication text available in evidence pack)* |
| Predicted New Indication | **None** — TxGNN prediction not yet available |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No prediction or supporting evidence available) |
| Taiwan Market Status | ❌ Not marketed (未上市) |
| Number of TFDA Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not output any predicted new indications for acetazolamide. Therefore, a mechanistic plausibility analysis cannot be performed at this time.

Detailed mechanism of action (MOA) data is also not available in this evidence pack. Based on publicly known information, acetazolamide is a sulfonamide derivative that acts as a potent carbonic anhydrase inhibitor. It reduces the formation of hydrogen and bicarbonate ions, leading to decreased aqueous humour secretion (relevant to glaucoma), altered renal bicarbonate reabsorption (relevant to diuresis and altitude sickness), and reduced neuronal excitability (relevant to epilepsy). Once the MOA data gap is filled and the TxGNN prediction pipeline is completed, a full mechanistic rationale can be provided.

---

## Clinical Trial Evidence

No predicted indication is available from TxGNN; therefore, no targeted clinical trial search was performed.

> Currently no related clinical trials registered for a predicted new indication.

---

## Literature Evidence

No predicted indication is available from TxGNN; therefore, no targeted literature search was performed.

> Currently no related literature available for a predicted new indication.

---

## Taiwan Market Information

Acetazolamide currently has **no TFDA-approved licenses** and is **not marketed in Taiwan**.

> No authorization records available.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack. The TFDA package insert query returned 1 result but the content was not parsed into the safety fields. It is recommended to retrieve and review the original package insert PDF for complete safety information.

---

## Data Gaps Summary

The following critical data gaps were identified and must be resolved before this candidate can advance:

| Gap ID | Category | Item | Severity | Impact | Remediation |
|--------|----------|------|----------|--------|-------------|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | **High** | Affects mechanistic relevance analysis | Query DrugBank API |

Additionally:
- **TxGNN prediction** has not been generated — the `predicted_indications` array is empty
- **Original indications** field is empty — needs to be populated from DrugBank or TFDA sources
- **DDI data** was queried but returned no results

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No new indication has been predicted by the TxGNN model, and there are multiple blocking-level data gaps. This candidate cannot proceed to evaluation until the prediction pipeline is completed and essential safety data is obtained.

**To proceed, the following is needed:**
1. **Run TxGNN prediction pipeline** for acetazolamide to generate candidate new indications
2. **Resolve DG001 (Blocking):** Download and parse the TFDA package insert to extract warnings and contraindications
3. **Resolve DG002 (High):** Query DrugBank API to retrieve the detailed mechanism of action
4. **Populate original indications** from DrugBank or regulatory sources (glaucoma, epilepsy, altitude sickness, heart failure, etc.)
5. **Re-query DDI databases** using alternative sources if the primary query returns no results
6. Once the above gaps are filled and a TxGNN prediction is available, regenerate this report for full evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

